APLS - Company ID 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.00B | $781.37M | $396.59M | $75.42M | $66.56M | $250.65M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $295.85M | $327.57M | $354.39M | $387.24M | $345.87M | $299.92M |
| SG&A |
Apellis Pharmaceuticals, Inc. reported annual revenue of $1.00B for fiscal year 2025. That is up 28.5% from $781.37M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $250.65M (FY 2020) to $1.00B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $550.26M |
| $501.05M |
| $500.81M |
| $277.16M |
| $176.77M |
| $139.40M |
| Operating income | $55.43M | -$164.98M | -$517.12M | -$594.61M | -$536.28M | -$213.73M |
| Income tax | $1.72M | $1.16M | $2.13M | $669.00K | $352.00K | $1.84M |
| Net income | $22.39M | -$197.88M | -$528.63M | -$652.17M | -$746.35M | -$344.87M |
| EPS (diluted) | $0.20 | -$1.60 | -$4.45 | -$6.15 | -$8.84 | -$4.59 |